Skip to main content

Table 1 Baseline characteristics

From: Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients

 

Total cohort

Klotho <460 pg/mL

Klotho >460 pg/mL

 

n = 127

n = 63

n = 64

Age, years

67 ± 7

67 ± 7

67 ± 8

Gender, female

30 (24%)

10 (16%)

20 (31%)*

Pulse pressure, mmHg

59 ± 24

59 ± 24

59 ± 16

Hypertension

104 (82%)

53 (87%)

51 (80%)

Diabetes

43 (34%)

24 (40%)

19 (30%)

Dialysis Modality, PD

42 (33%)

8 (13%)

34 (53%)***

Dialysis vintage, years

2.3 ± 2

2.6 ± 2.7

2.0 ± 2.2

RRF, (ml/min/1.73 m2)

1.8 ± 1.6

1.7 ± 1.8

2.0 ± 1.4

Anuria

30 (24%)

20 (33%)

10 (16%)*

Phosphate (mmol/L)

1.5 ± 0.4

1.6 ± 0.4

1.5 ± 0.4

Calcium (mmol/L)

2.4 ± 0.2

2.4 ± 0.2

2.4 ± 0.2

FGF-23 (RefU/mL)

7247 ± 16815

8723 ± 21627

5794 ± 10044

25(OH)D (nmol/L)

87 ± 57

102 ± 65

71 ± 42**

PTH (pmol/L)

35 ± 34

42 ± 41

28 ± 22*

Creatinine (umol/L)

659 ± 202

642 ± 211

676 ± 195

CRP (mg/L)

14.3 ± 30.7

20.1 ± 41.7

8.9 ± 12.22*

β -blocker

71 (56%)

37 (60%)

34 (54%)

ACEi

32 (25%)

19 (31%)

13 (21%)

ARB

37 (29%)

13 (21%)

24 (38%)*

Statin

79 (62%)

43 (69%)

36 (57%)

NCPB

107 (84%)

54 (87%)

53 (84%)

CCPB

50 (39%)

25 (40%)

25 (40%)

Cinacalcet

15 (12%)

7 (12%)

8 (13%)

  1. PD; Peritoneal dialysis, RRF; Residual Renal Function, FGF-23; Fibroblast Growth Factor 23. PTH; Parathyroid hormone, ACEí; Angiotensin Converting Enzyme inhibitor, ARB; Angiotensin receptor blocker, NCPB; Non calcium containing phosphate binder, CCPB; Calcium containing phosphate binder. *;p < 0.05, **;p < 0.01; ***;p < 0.001.